These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3546 related articles for article (PubMed ID: 32439799)

  • 1. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.
    Jochems C; Hodge JW; Fantini M; Tsang KY; Vandeveer AJ; Gulley JL; Schlom J
    Int J Cancer; 2017 Aug; 141(3):583-593. PubMed ID: 28477372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.
    Jochems C; Hodge JW; Fantini M; Fujii R; Morillon YM; Greiner JW; Padget MR; Tritsch SR; Tsang KY; Campbell KS; Klingemann H; Boissel L; Rabizadeh S; Soon-Shiong P; Schlom J
    Oncotarget; 2016 Dec; 7(52):86359-86373. PubMed ID: 27861156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
    Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X
    Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
    Bajor M; Graczyk-Jarzynka A; Marhelava K; Burdzinska A; Muchowicz A; Goral A; Zhylko A; Soroczynska K; Retecki K; Krawczyk M; Klopotowska M; Pilch Z; Paczek L; Malmberg KJ; Wälchli S; Winiarska M; Zagozdzon R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34
    Ghaedrahmati F; Akbari V; Seyedhosseini-Ghaheh H; Esmaeil N
    Stem Cell Res Ther; 2024 Aug; 15(1):257. PubMed ID: 39135206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
    J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms.
    Mensali N; Dillard P; Fayzullin A; Köksal H; Gaudernack G; Kvalheim G; Inderberg EM; Wälchli S
    FASEB J; 2021 Sep; 35(9):e21750. PubMed ID: 34424568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
    Giles AJ; Hao S; Padget M; Song H; Zhang W; Lynes J; Sanchez V; Liu Y; Jung J; Cao X; Fujii R; Jensen R; Gillespie D; Schlom J; Gilbert MR; Nduom EK; Yang C; Lee JH; Soon-Shiong P; Hodge JW; Park DM
    JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31536478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R; Schlom J; Hodge JW
    J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor.
    Myers Chen K; Grun D; Gautier B; Venkatesha S; Maddox M; Zhang AH; Andersen P
    Front Immunol; 2024; 15():1380065. PubMed ID: 38726005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
    Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
    J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
    Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 178.